Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia

Kazu Nakazawa¹, Vivek Jeevakumar¹ and Kazuhito Nakao¹

The N-methyl-D-aspartate receptor hypofunction is one of the most prevalent models of schizophrenia. For example, healthy subjects treated with uncompetitive N-methyl-D-aspartate receptor antagonists elicit positive, negative, and cognitive-like symptoms of schizophrenia. Patients with anti-N-methyl-D-aspartate receptor encephalitis, which is likely caused by autoantibody-mediated down-regulation of cell surface N-methyl-D-aspartate receptors, often experience psychiatric symptoms similar to schizophrenia initially. However, where and when N-methyl-D-aspartate receptor hypofunction occurs in the brain of schizophrenic patients is poorly understood. Here we review the findings from N-methyl-D-aspartate receptor antagonist and autoantibody models, postmortem studies on N-methyl-D-aspartate receptor subunits, as well as the global and cell-type-specific knockout mouse models of subunit GluN1. We compare various conditional GluN1 knockout mouse strains, focusing on the onset of N-methyl-D-aspartate receptor deletion and on the cortical cell-types. Based on these results, we hypothesize that N-methyl-D-aspartate receptor hypofunction initially occurs in cortical GABAergic neurons during early postnatal development. The resulting GABA neuron maturation deficit may cause reduction of intrinsic excitability and GABA release, leading to disinhibition of pyramidal neurons. The cortical disinhibition in turn could elicit glutamate spillover and subsequent homeostatic down regulation of N-methyl-D-aspartate receptor function in pyramidal neurons in prodromal stage. These two temporally-distinct N-methyl-D-aspartate receptor hypofunctions may be complimentary, as neither alone may not be able to fully explain the entire schizophrenia pathophysiology. Potential underlying mechanisms for N-methyl-D-aspartate receptor hypofunction in cortical GABA neurons are also discussed, based on studies of naturally-occurring N-methyl-D-aspartate receptor antagonists, neuregulin/ErbB4 signaling pathway, and theoretical analysis of excitatory/inhibitory balance.

npj Schizophrenia (2017) 3:7 ; doi:10.1038/s41537-016-0003-3

INTRODUCTION

Schizophrenia is a devastating, chronic psychiatric disorder that is marked by complex and heterogeneous symptoms, such as positive (e.g. hallucinations and delusions), negative (e.g. anhedonia and social withdrawal), and cognitive symptom (i.e. difficulty in attention, memory and executive functions). Much about the etiology and pathophysiology of schizophrenia remains unknown. The dominant hypothesis has implicated hyperactivity of the dopaminergic system.¹ However, antipsychotics, which mainly block dopamine D2 receptors, show poor efficacy in alleviating the negative and cognitive symptoms. On the other hand, the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis has been particularly successful at explaining all of these symptoms associated with schizophrenia.² The uncompetitive or open-channel NMDAR antagonists, such as low-dose of phencyclidine (PCP) and ketamine, induce a psychotic state that resembles schizophrenia more closely than dopamine agonists, because they elicit positive symptoms as well as negative symptoms and cognitive deficits.³ Pharmacological intervention with NMDAR antagonists appears to model much of the phenomenology of schizophrenia. However, it remains largely unknown regarding what mechanisms or molecules elicit NMDAR hypofunction that potentially leads to schizophrenia in humans. In order to probe for such mechanisms/molecules, it is important to identify the spatial and temporal boundary condition for NMDAR hypofunction in schizophrenia. In other words, we need to determine where and when functional down-regulation of NMDARs occurs endogenously. Research on uncompetitive NMDAR antagonist-induced psychosis and on anti-NMDAR encephalitis, which often causes schizophrenia-like psychosis, has provided some important clues. However, a more straightforward approach has been to analyze genetically-engineered animal models with cell-type selective ablation of NMDARs. In this review, several significant findings stemming from these clinical cases and preclinical models are discussed that are relevant for understanding the spatial and temporal boundaries of NMDAR hypofunction.

DRUG MODEL SUPPORTING NMDAR HYPOFUNCTION

Both PCP⁴ and ketamine⁵ exacerbate positive and negative symptoms in pre-existing schizophrenia, suggesting a shared mechanism with schizophrenia pathophysiology. Indeed, both NMDAR antagonists lead to increase the power of cortical gamma oscillations⁶ and in functional connectivity.⁷ The antagonists also induce disturbance in the GABAergic system such as a loss of glutamic acid decarboxylase-67 (GAD67) and parvalbumin (PV), which are consistently reported in postmortem brains of
A recent report has revealed a selective localization of synaptic NMDARs at the feed-back synapses on PV neurons. A recent study showed that low concentrations of the NMDAR antagonists PCP and memantine preferentially inhibit mainly PV-containing. Also, ex vivo data show that GluN2D-containing NMDARs are less-sensitive to Mg2⁺ blockade. A series of studies by Ikeda and colleagues demonstrated that GluN2D knockout mice are insensitive to PCP or ketamine treatment. For example, PCP increases locomotor activity and extracellular dopamine levels in the striatum and prefrontal cortex, but this increase is not found in GluN2D knockout mice. Suggesting that GluN2D-containing NMDARs are responsible for some of the effects of PCP. Similarly, ketamine-induced baseline gamma power increases are also abolished in GluN2D knockout mice. These results may suggest that NMDAR antagonists are effective preferentially at GluN2D-containing GABA neurons, leading to schizophrenia-like phenotypes in mice. Taken together, acute NMDAR antagonist-induced psychosis in adulthood appears to be mediated, at least in part, by the GluN2D-containing NMDARs in the hippocampal GABA neurons including PV neurons.

However, repetitive or subchronic treatment of NMDAR antagonists in adulthood may produce more robust phenotypes than those seen following acute treatment. For example, acute administration of NMDAR antagonists increases dopamine level in mPFC, while their long-term treatment results in the reduction of dopamine release in the prefrontal cortex in rats and monkeys. Since amphetamine-induced dopamine release in prefrontal cortex appears to be compromised in patients with schizophrenia, chronic treatments may be a better model the dopamine phenotype in prefrontal cortex. Intensive research to identify changes in the brain following repetitive administration of NMDAR antagonists has been reviewed elsewhere.

AUTOANTIBODY MODEL SUPPORTING NMDAR HYPOFUNCTION

Compelling clinical evidence supporting the NMDAR hypofunction theory of schizophrenia also comes from studying anti-NMDAR encephalitis. Anti-NMDAR encephalitis is recently described as one of most common synaptic autoimmune disorders. Clinical expression of this disease consists of a variable presentation of psychiatric symptoms such as hallucinations, delusions, mania, catatonia, and insomnia days after the prodromal phase. About 65% of adults first present with psychiatric symptoms and the majority are initially assessed by the psychiatric services. IgG antibodies targeting the extracellular domain of the GluN1 subunit of the NMDAR are likely to be the main pathogenesis of the disease. NMDAR downregulation seems to be due to the reduction of surface NMDARs resulting from antibody-mediated crosslinking of NMDARs leading to internalization of the receptors. Receptor internalization occurs at the same degree in both excitatory and inhibitory neurons, reaching plateau 12 h after auto-antibody treatment in cultured hippocampal neurons. Consequently, NMDAR-mediated mini-EPSC amplitudes in the pyramidal neurons are significantly reduced 24 h after the antibody added to the cultured cells, while NMDA component in the GABA neurons has not been tested. Because the antibody does not inhibit the NMDA currents, NMDAR hypofunction is likely a result of lower expression of surface receptors, but not due to the functional channel blocking currents. Therefore, initial presentation of psychiatric symptoms could be associated with the cell-types in which NMDARs are first robustly internalized. Quantitative immunogold electron microscopic study in rat hippocampus showed that GluN1 density is highest in pyramidal cell spines and lowest in dendrites of PV neurons in stage. Antibody-mediated NMDAR internalization at the PV-positive GABA neurons, which depletes cell-surface NMDARs quickly, may be linked to the initial psychiatric symptoms. When the cerebrospinal fluid (CSF) antibody titers get higher, the pyramidal neurons’ NMDARs may also be depleted from the cell surface leading to additional symptoms. Indeed, CSF antibody titers have been shown to be related to the illness severity of various schizophrenia. Ketamine also increases the glutamate levels in prefrontal cortex or hippocampus in human 1H-MRS studies, which is consistent with the elevated glutamate observed in schizophrenia. Likewise, NMDAR hypofunction models based on the actions of PCP and ketamine have become increasingly well established, as a major tenet of glutamatergic dysfunction theory of schizophrenia. However, potential mechanisms by which PCP and ketamine lead to these changes have been debated. Acute systemic treatment with MK-801 in rats has been shown to preferentially block NMDARs on the medial prefrontal cortex (mPFC) GABAergic interneurons, leading to a reduction of GABAergic network function and a subsequent increase in pyramidal cell firing due to disinhibition. Curiously, a local infusion of PCP or MK-801 directly into mPFC does not evoke the excitatory responses of the local pyramidal neurons in awake rats. In contrast, local MK-801 infusion to hippocampal CA1 in adult rats reproduced the disinhibitory effect of systemic MK-801 on the mPFC pyramidal neuron firings. Therefore, Jodo suggested that MK801-induced excitability of mPFC pyramidal neurons likely results from the activation of excitatory inputs in the ventral part of the hippocampus, which is known to send a dense monosynaptic glutamatergic projection to the mPFC superficial layer.

It is still unclear how locally applied MK-801 results in differential effects on the pyramidal neuron activities of the mPFC and hippocampus. One intriguing possibility is that mPFC pyramidal neurons in vivo are more susceptible to the MK-801 blockade, presumably due to their GluN2B-mediated persistent activity. In vivo intra-PFC iontophoresis of MK-801 into the primate dorsolateral PFC resulted in a marked decrease in the task-related firing of pyramidal cells, suggesting that NMDARs are involved in up-state or burst firing in mPFC. In contrast, NMDARs in the hippocampal pyramidal cells are crucial for synaptic plasticity induction, but they show little effect on the burst firing per se. Thus, the spatial tunings, but not the firing rates, of place cell activity are compromised by NMDAR antagonists and by genetic deletion of NMDAR obligatory subunit GluN1 (NR1). Moreover, it has been reported that over 60% of the hippocampal complex-spike cells are silent during the exploration of spatial environment and do not display place cell activity. It is plausible that these “silent” hippocampal principal cells are less sensitive to uncompetitive NMDAR antagonists.

In any case, there are critical localization of synaptic NMDARs at the feed-back synapses from the recurrent collaterals, but not at the feed-forward synapses from Schaffer-collateral inputs, of CA1 pyramidal cells (but see ref. 22). Importantly, the feed-back synaptic input to PV-containing neurons appears to be crucial for their spike timing precision, thereby regulating the emergence of theta/gamma oscillations. Indeed, PCP treatment disrupts type I (atropine-resistant) theta oscillations and increases gamma power in area CA1 in vivo. GluN1 ablation in PV neurons also resulted in exactly the same phenotypes; a disruption of type I theta oscillations, and an increase in spontaneous gamma oscillations in the hippocampus. These results strongly suggest that PCP acts at NMDARs of the feed-back synapses on PV neurons in adulthood.

Another recent study showed that low concentrations of the NMDAR antagonists PCP and memantine preferentially inhibit tonically-active extrasynaptic NMDARs on the CA1 interneurons containing GluN2D in adult mice. Interestingly, tonic NMDARs have a more prominent contribution to the intrinsic excitation in GABA neurons than in pyramidal neurons, which is consistent with the excessive disinhibition by NMDAR antagonists in the hippocampus.

It is noted that expression of GluN2D-containing NMDARs is largely confined to cortical and hippocampal GABA neurons, which is consistent with the elevated glutamate observed in schizophrenia. This increased glutamatergic dysfunction theory of schizophrenia. However, potential mechanisms by which PCP and ketamine lead to these changes have been debated.

Acute systemic treatment with MK-801 in rats has been shown to preferentially block NMDARs on the medial prefrontal cortex (mPFC) GABAergic interneurons, leading to a reduction of GABAergic network function and a subsequent increase in pyramidal cell firing due to disinhibition. Curiously, a local infusion of PCP or MK-801 directly into mPFC does not evoke the excitatory responses of the local pyramidal neurons in awake rats. In contrast, local MK-801 infusion to hippocampal CA1 in adult rats reproduced the disinhibitory effect of systemic MK-801 on the mPFC pyramidal neuron firings. Therefore, Jodo suggested that MK801-induced excitability of mPFC pyramidal neurons likely results from the activation of excitatory inputs in the ventral part of the hippocampus, which is known to send a dense monosynaptic glutamatergic projection to the mPFC superficial layer.

It is still unclear how locally applied MK-801 results in differential effects on the pyramidal neuron activities of the mPFC and hippocampus. One intriguing possibility is that mPFC pyramidal neurons in vivo are more susceptible to the MK-801 blockade, presumably due to their GluN2B-mediated persistent activity. In vivo intra-PFC iontophoresis of MK-801 into the primate dorsolateral PFC resulted in a marked decrease in the task-related firing of pyramidal cells, suggesting that NMDARs are involved in up-state or burst firing in mPFC. In contrast, NMDARs in the hippocampal pyramidal cells are crucial for synaptic plasticity induction, but they show little effect on the burst firing per se. Thus, the spatial tunings, but not the firing rates, of place cell activity are compromised by NMDAR antagonists and by genetic deletion of NMDAR obligatory subunit GluN1 (NR1). Moreover, it has been reported that over 60% of the hippocampal complex-spike cells are silent during the exploration of spatial environment and do not display place cell activity. It is plausible that these “silent” hippocampal principal cells are less sensitive to uncompetitive NMDAR antagonists.

In any case, there are critical localization of synaptic NMDARs at the feed-back synapses from the recurrent collaterals, but not at the feed-forward synapses from Schaffer-collateral inputs, of CA1 pyramidal cells (but see ref. 22). Importantly, the feed-back synaptic input to PV-containing neurons appears to be crucial for their spike timing precision, thereby regulating the emergence of theta/gamma oscillations. Indeed, PCP treatment disrupts type I (atropine-resistant) theta oscillations and increases gamma power in area CA1 in vivo. GluN1 ablation in PV neurons also resulted in exactly the same phenotypes; a disruption of type I theta oscillations, and an increase in spontaneous gamma oscillations in the hippocampus. These results strongly suggest that PCP acts at NMDARs of the feed-back synapses on PV neurons in adulthood.

Another recent study showed that low concentrations of the NMDAR antagonists PCP and memantine preferentially inhibit tonically-active extrasynaptic NMDARs on the CA1 interneurons containing GluN2D in adult mice. Interestingly, tonic NMDARs have a more prominent contribution to the intrinsic excitation in GABA neurons than in pyramidal neurons, which is consistent with the excessive disinhibition by NMDAR antagonists in the hippocampus.

It is noted that expression of GluN2D-containing NMDARs is largely confined to cortical and hippocampal GABA neurons, which is consistent with the elevated glutamate observed in schizophrenia. This increased glutamatergic dysfunction theory of schizophrenia. However, potential mechanisms by which PCP and ketamine lead to these changes have been debated.
encephalitic symptoms.44 It may be worth assessing whether NMDAR internalization at PV neurons is associated with the psychiatric symptoms of this disorder. Notably, the prevalence of anti-NMDAR autoantibodies in populations with primary schizophrenia appears to be low.43 However, the discovery of NMDAR autoantibodies associated with acute psychosis strongly reinforces the NMDAR hypofunction model of schizophrenia as a biological basis for mental illness.

**DEVELOPMENTAL ASPECT OF NMDAR HYPOFUNCTION**

Although drug- and autoantibody-mediated NMDAR hypofunction models, which occur in adulthood, show phenomenological validity, pathophysiology of schizophrenia itself remains unexplained. Schizophrenia is a neurodevelopmental disorder and insults to the developing brain can contribute significantly to the manifestation of the disorder in young adulthood.50 Therefore, the above models are unlikely to be able to replicate the neurobiological changes that occur over time in the schizophrenic brain. Instead, accumulating evidence suggests that transient NMDAR blockade in perinatal period confers long-lasting brain and behavior change. For example, maternal abuse of PCP during pregnancy increases the risk of the fetus developing schizophrenia later in life.46,47 Similarly, ketamine anesthesia during the pregnancy increases the risk of the fetus developing schizophrenia. For example, maternal abuse of PCP during blockade in perinatal period confers long-lasting brain and logical changes that occur over time in the schizophrenic brain.

Fig. 1 Summary of schizophrenia-related phenotypes in various GluN1 mutant mice. GluN1 knockdown regardless of cell-types (“hypomorph mouse”) presents several aspects of schizophrenia-related signs. GluN1 deletionin glutamatergic neurons (Emx1-cre KO and Ncx-cre KO) during development both result in the phenotypes too severe to consider as schizophrenia-related signs. GluN1 deletion in forebrain principal neurons in adulthood (G35-3 cre-KO and αCaMKII cre-KO) appears to be sufficient to cause some neuropsychiatric signs, including E/I balance increase and cognitive dysfunction; however, insufficient to induce abnormalities of local GABA neurons seen in schizophrenia pathophysiology. Mouse strains with black arrows (top two strains) received genetic manipulation targeted to all the cells throughout the development. The manipulation in the mouse with blue arrows (bottom three strains) was largely restricted to the particular cell-types of forebrain principal neurons. Thick arrows in the left panel show the period of knockout occurring in the designated KO cell-type in the cortex. Hyphen denotes no data in the right Table. ROS reactive oxygen species. PPI, prepulse inhibition of startle reflex

Genetically-Engineered Global NMDAR Hypofunction

Having no off-target effects, genetically-engineered mice have been excellent tools to assess the spatial and temporal boundary conditions of NMDAR hypofunction (Fig. 1). Though complete genetic ablation of GluN1, a vital subunit of NMDARs, may lead to an overly pronounced phenotype that does not share the genetic basis of schizophrenia, it may be a useful tool to model the effect of NMDAR antagonists as it leads to a functional blockade of the receptor. Conventional GluN1 knockout mice are not viable, dying 8–15 h after the birth.72 However, careful analyses revealed severe disruption of somatosensory barrel cortex formation,73 which appears more sensitive than that of schizophrenia pathology. Furthermore, corpus callosum development is rather accelerated in both the mutants and GluN1 haploinsufficient (+/-) mice compared to the wild type mice.74 In contrast, the volume of

---

**Table 1**

| GluN1 KO Cell-type | Baseline EEG | GAD67 | ROS | Cognitive | Social | Anxiety | Locomotor | PPI | Ref. |
|--------------------|-------------|-------|-----|-----------|--------|---------|-----------|-----|------|
| All cells (embryonic) | — | — | — | — | — | — | — | 72 to 74 |
| Cortical Pyramidal neurons | — | — | — | — | — | — | — | 95 to 97 |
| Cortical L2/3 Pyramidal neurons | — | — | — | — | — | — | — | 98, 99 |
| Forebrain Principal neurons | — | — | — | — | — | — | — | 100 to 102 |

---

Published in partnership with the Schizophrenia International Research Society npj Schizophrenia (2017) 7
central corpus callosum is known to be significantly decreased in schizophrenia, with effects more detectable in first-episode than chronic schizophrenia. In this context, global NMDAR hypofunction in the late gestation period is unlikely to take place in schizophrenia pathogenesis.

Several genetically-engineered mouse models have been generated to overcome the neonatal lethality of GluN1 conventional knockout mice. Among them, a notable model is a GluN1 “hypomorph” mouse line, which was generated by inserting the neomycin cassette into the GluN1 gene, thereby resulting in the GluN1 protein expression approximately 10% of the normal level that survived to adulthood (Fig. 1). Subsequent studies found decreased PPI, sociability and mating behavior as well as impaired olfaction and increased locomotor activity. Based on these findings, GluN1 hypomorph mutant strain has been described as a transgenic model of schizophrenia. However, behavioral anomalies began to appear before the weaning, and the adult mutants displayed robust impairments in short and long-term memory, on both spatial and non-spatial tasks, which made it difficult to dissociate a mnemonic phenotype from a more general performance deficit. Siegel and colleagues also investigated sensory event-related potentials (ERPs) of this strain and found a significant sensory disinhibition; but its ERP pattern was atypical for patients with schizophrenia, rather closely resembles what is seen in autism. These findings indicate that GluN1 hypomorph mice may show a more global impairment rather than that which belongs to any specific disease. Hence, it is expected that region-specific or cell type-specific deletions of GluN1 subunit may uncover more precise contribution of NMDARs to the emergence of the schizophrenia-like phenotypes.

**NMDAR HYPOFUNCTION TARGETED TO CORTICAL EXCITATORY NEURONS**

Alteration of NMDAR subunit GluN1 mRNA has been often reported to decrease by 15–30% in the post-mortem brains with schizophrenia patients, while some reports showed no change or an increase. Although the findings are conflicting, one may speculate that GluN1 expression may be down-regulated in the cortex and hippocampus of patients with schizophrenia (see review by 92,93), which could lend support for NMDAR hypofunction in the cortical and hippocampal pyramidal neurons. Additionally, even if the receptor levels were not lowered, postsynaptic NMDA signaling, such as Src kinase, may still be down-regulated in schizophrenia. However, it is unclear regarding which developmental stage such NMDAR hypofunction takes place in pyramidal neurons in patients with schizophrenia. In animal studies, several genetically-engineered mouse strains in which GluN1 ablation was targeted to cortical and hippocampal glutamatergic excitatory neurons have been analyzed. Two embryonic GluN1 knockout mouse strains were generated, in both of which the NMDAR deletion is selective to cortical and hippocampal glutamatergic neurons have been analyzed. Two embryonic GluN1 knockout mouse strains were generated, in both of which the NMDAR deletion is selective to cortical and hippocampal glutamatergic neurons. These mutant mice showed cognitive dysfunction or “noise”. Consistently, oCamKII-GluN1 knockout mice showed a broadband LFP power increase and an impaired evoked power regardless of the frequency at area CA3 in the auditory paired-click paradigm. Combined with behavioral data showing impairment in spatial working memory and reduced nest building and social activity, it was proposed that NMDAR hypofunction in pyramidal neurons is sufficient to cause schizophrenia-related changes. In this study, however, NMDAR knockout in pyramidal neurons did not recapitulate a dysfunction of local GABAergic neurons, such as a reduction of GAD67 and PV mRNAs, which is consistently reported in the postmortem brain of schizophrenia. Together with our previous report, pyramidal neuron-NMDAR hypofunction in adulthood appears to cause neuropsychiatric signs, including E/I balance increase and cognitive dysfunction; however, insufficient to induce abnormalities of local GABA neurons seen in schizophrenia pathophysiology.

**NMDAR HYPOFUNCTION TARGETED TO CORTICAL PV NEURONS**

Despite the abundance of NMDAR expression in the cortical and hippocampal pyramidal neurons, systemic administration of uncompetitive NMDAR antagonists (PCP, ketamine and MK-801) in rodents has been consistently demonstrated to increase E/I balance and enhance disinhibition (reviewed by 104–108). Importantly, in vivo effects of MK-801 first appeared as reduced activity of GABA neurons, followed by increased activity of pyramidal neurons in mPFC. It has also been shown ex vivo that hippocampal GABAergic interneurons are disproportionately more sensitive to NMDAR antagonists than pyramidal neurons. Although the reason why uncompetitive NMDAR antagonists preferentially impact GABA neurons is not completely understood, at least two mechanisms are suggested. First, local GABA neurons, in particular, fast-spiking neurons containing PV, are known to fire action potentials at much higher frequency than pyramidal neurons and the interneurons positive for somatostatin, vasoactive-intestinal-polypeptide or neuropeptide Y. Therefore, the channel pore Mg2+ occlusion may be relieved by constant depolarization. Second, ketamine is reported to preferentially inhibit GluN2C- and GluN2D-containing NMDARs in artificial CSF with physiological Mg2+ concentration, presumably due to their reduced affinity to Mg2+. Importantly, GluN2D-containing NMDAs are selectively distributed in PV-positive and/or
Fig. 2  Summary of schizophrenia-related phenotypes in various GluN1 mutant mice, in which GluN1 knockout is targeted to GABA neurons. GluN1 deletion during the embryonic stage in migrating forebrain Dlx5/6-positive GABAergic cells lead to lethality(Dlx5/6 cre KO). In contrast, GluN1 deletion after postnatal 4 weeks in PV neurons (PV-cre KO) or after adolescence in Ppp1r2-positive GABA neurons (bottom strain) produce less phenotypes compared to the mutant mice that received GluN1 deletion in GABA neurons in early postnatal period (Ppp1r2 cre-KO starting from PND 7). Thus, it appears that early postnatal period, but not during the embryonic stage or after adolescence, is a critical period of GABAergic NMDAR hypofunction leading to schizophrenia. Arrow shows the period of knockout occurring in the designated KO cell-type in the cortex. The level of intrinsic property maturation of neocortical fast-spiking neurons largely based on Refs. 68,69. Relative change in synaptic evoked NMDA component estimated from the data in Ref. 22 for hippocampal PV neurons and Ref. 65 for mPFC PV neurons. Hyphen denotes no data. The data of Dlx5/6 cre-KO mice is unpublished. ROS reactive oxygen species. PPI, prepulse inhibition of startle reflex.

somatostatin-positive interneurons of the cortex and hippocampus in adulthood.110,111,112 Therefore, a specific deficit in NMDAR signaling in fast-spiking PV neurons may explain certain aspects of NMDAR hypofunction-mediated schizophrenia-related phenotypes.

To test this hypothesis, conditional deletion of the GluN1 subunit selectively in PV-positive cells was achieved by two groups, using the same PV-cre line, which was produced by Silvia Arbor’s lab, with a floxed-GluN1 line distinct each other,24,112 (Fig. 2). Both PV-cre/GluN1 KO mutants demonstrated cortical and hippocampal disinhibition and the baseline gamma power increase. More importantly, induction of gamma oscillation driven by PV neuron-selective optogenetic activation was impaired in the mutants;112 which strongly supports the idea that PV neuron is necessary for generation of gamma-band oscillations.113,114

Notably, baseline gamma power increase and sensory-evoked gamma oscillation deficits are consistently demonstrated by NMDAR antagonist exposure to animals6 and in EEG/MEG studies in patient with schizophrenia.115 Furthermore, in vivo MK-801 action on PV neurons was supported by the finding that MK-801-induced stereotypies are undetectable in the PV-cre/GluN1 KO mutant mice.112 The mutants also showed selective impairments in habituation, short-term memory, sociability and vocalizations, although they displayed normal PPI for acoustic startle reflex and nest building behavior.24,112,116 (Nakazawa, unpublished). One probable reason for less behavioral deficits compared to those observed in the Ppp1r2cre/GluN1 KO mutants (see below for details) may be related to the onset of GluN1 knockout in PV neurons. Immunocytochemistry data suggest that the onset of GluN1 knockout is within 4–8 weeks of age for both mutants,112,116 which is much later than the maturation period of the fast-spiking property of PV neurons (PND 6–21).68,69). Actually, the evoked NMDA components on the glutamatergic synapses in PV neurons in the mPFC68,69 and hippocampus25 seem to be diminished by PND 21–28. Alternatively, additional NMDAR deletion in other GABA neurons, like Reelin-positive GABA neurons, may also be important for the robust behavioral phenotypes, because approximately 30% of Reelin-positive GABA neurons are also Cre-targeted in the cortex and hippocampus of the Ppp1r2cre mouse strain.116

**NMDAR HYPOFUNCTION TARGETED TO GABA NEURONS IN DEVELOPMENT**

We predicted that NMDAR knockout in GABA neurons during a much earlier developmental period may be necessary to produce more robust phenotypes. To target the GluN1 ablation into GABA neurons in development, we crossed the floxed-GluN1 mouse to a Dlx5/6-cre line, in which Cre recombination occurs in migrating forebrain GABA neurons of the embryonic brain.117 However, we found that no homozygously-floxed mutant mice survived, suggesting that NMDAR function in migrating GABA neurons is fundamental for brain development and survival, but beyond the schizophrenia pathophysiology (Nakazawa, data not shown).

To target the GluN1 ablation into early postnatal development of GABA neurons, we crossed the floxed-GluN1 mouse to a Ppp1r2-cre line, in which Cre expression is detected by PND 7 in 40–50% of cortical and hippocampal GABA neurons.66,107 (Fig. 2). In the somatosensory (S1) cortex, about 70% of cre-targeted neurons are PV containing, and the rest includes Reelin-positive neurons, but negligible in the pyramidal neurons. Since cre recombination occurs in over 80, 75, and 90% of PV neurons in the neocortex, mPFC and hippocampus, respectively, it is expected to confer efficient genetic manipulation in PV neuron cell-type. Genetic ablation of GluN1 in Ppp1r2-positive neurons results in a variety of behavioral abnormalities, such deficits in as spatial and social short-term memory, nest building, and PPI. The mutants also displayed increased anxiety-like behavior in the elevated plus maze and open field, and novelty-induced hyper locomotion. Interestingly, most behavioral abnormalities appeared after young adulthood (8 weeks old), some of which were exacerbated by the social isolation stress.66,118 Furthermore, in vivo awake LFP/unit recordings showed not only an increased pyramidal cell firing and their action-potential spike synchrony deficits in S1 cortex but also revealed a baseline broadband LFP power increase and impaired tone-evoked gamma power amplitude and phase.
locking in primary auditory cortex.119 These physiological phenotypes are shared with PV-cre/GluN1 KO mutants, suggesting that these gamma synchrony deficits are attributed to GluN1 deletion in PV neurons. Interestingly, auditory tone stimulation also evoked prolonged activation of mutants’ auditory deep layer pyramidal neurons in a 5-HT2A receptor-dependent manner (Nakao et al., unpublished). Moreover, hypo-dopaminergic state in mPFC and hyperdopaminergic state in the striatum appears to co-occur in this mutant brain (Nakao et al., unpublished). Therefore, both serotonin and dopamine dysregulation, which are reminiscent of schizophrenia, appear to be a downstream event of developmental NMDAR hypofunction in GABA neurons. Interestingly, when GluN1 was deleted in the Ppp1r2 neurons after 8 weeks of age (because the recombination onset was delayed in another floxed-GluN1 line used), we found no behavioral or dopaminergic impairments. Therefore, early postnatal period, after gestation period but before adolescence, appeared to be a critical period during which NMDAR hypofunction can induce the emergence of schizophrenia-like phenotypes (Fig. 2). A drawback with using the Ppp1r2cre line is that the knockout occurs not only in local PV neurons but also in other cortical GABA neurons, including Reelin-positive interneurons. Cre expression is also detected in a majority of neurons of tenia tecta and lateral septum, and a subset of neurons in superior colliculus superficial layers. Thus, behavioral deficits of the mutants could be attributed to abnormalities of such subcortical GABA neurons. Interestingly, Cre expression is detected only 5% GABA neurons of thalamic reticular nucleus in Ppp1r2cre line, which are mostly positive for PV. Further studies are warranted to determine if the early postnatal PV neurons are the locus of NMDAR hypofunction.

### ADDITIONAL FINDINGS SUPPORTING NMDAR HYPOFUNCTION IN CORTICAL GABA NEURONS

The evidence for NMDAR hypofunction in GABA neurons is scarce. However, a recent postmortem meta-analysis quantifying NMDAR subunit expression in the prefrontal cortex of people with schizophrenia found a reduction of GluN2C subunit mRNA in all three studies examined.120 Expression of cortical GluN2C subunit is confined to subsets of interneurons in the cortex. Therefore, a GluN2C expression deficit could account for NMDAR hypofunction in GABA neurons in schizophrenia. Another postmortem study demonstrated a lower density of excitatory synapses on PV-positive interneurons in FCx of patients with schizophrenia, while the glutamate receptor subtypes were unidentified.120 This could be due to a deficit in excitatory synapse formation on PV neurons, or due to reduced synaptic input from excitatory neurons.

It then must be considered whether there are any potential mechanisms that cause NMDAR hypofunction in GABA neurons during the perinatal stage. A series of endogenous NMDAR antagonist studies allows us to speculate that these antagonists may preferentially act on the NMDARs in the GABA neurons. For example, kynurenic acid (KYN) is a naturally occurring antagonist of NMDAR at the glycine binding site.121 A KYN synthesizing enzyme, kynurenine aminotransferase II (KAT II) is known to be responsible for brain KYN synthesis. Interestingly, a recent immunocytochemical study in mice demonstrated that KAT II is expressed predominantly in GABAergic neurons as well as in astrocytes, but much less in the pyramidal cells in the cortex and hippocampus, raising a possibility that locally-secreted KYNs preferentially inhibits NMDARs in GABA neurons.122 Notably, the brain levels of KYN are elevated in schizophrenia and by the neuroinflammatory stress, which exists in schizophrenia as well.121 Mounting preclinical evidence also suggest that KAT II-selective inhibitors produce a pro-cognitive effect in schizophrenia-relevant behavioral assays.123 Another study also reported that the effect of KYN-induced NMDAR blockade on the neuronal differentiation in vitro is more prominent on GABAergic neuron lineage compared to glutamatergic neurons, although the underlying mechanisms of the preferential action to GABA neurons is unclear.124

Another endogenous NMDAR antagonist which is known to bind to GABAergic NMDARs is a class of sulfated neuroactive steroids, including pregnanolone sulfate (3αSβ5; 20-Oxo-5β-pregnan-3α-yl-sulfate) and pregnenolone sulfate (20-Oxo-pregnen-5α-en-3α-yl sulfate). These compounds are known to act as a use-dependent allosteric NMDAR antagonist, while they also modulate the GABA_A receptor.125 The levels of the neurosteroids increase towards parturition during pregnancy126 and by the acute stressor. Interestingly, it has been reported that these sulfated neurosteroids preferentially bind to tonic NMDARs containing GluN2C and/or GluN2D.127 Unexpectedly, however, systemic infusion of the neurosteroid did not elicit psychotomimetic-like behavior in rats, and it rather ameliorated MK-801-induced behavioral deficits.128 Therefore, further study is warranted to determine the action of these steroids and to what extent they inhibit tonic NMDARs in GABA neurons.

If these events would actually occur in the schizophrenia brain, NMDAR hypofunction in GABA neurons might be the secondary event to environmental insults. However, certain genetic mechanisms may also explain GABAergic NMDAR hypofunction. Buonanno’s team elegantly showed a selective internalization of NMDARs from the cell surface of the cortical ErbB4-expressing GABA neurons, but not in the pyramidal neurons in hippocampal cell culture prepared from E19 rat pups.129 ErbB4 and its ligand neuregulin (NRG)-2 are predominantly co-expressed in the PV-containing GABA neurons, but not in the pyramidal neurons in the cortex. Dysregulated ErbB4 splicing is known to associate with PV neurons in schizophrenia.130 They demonstrated that NMDARs in GABA neurons are required to release NRG2, which activate its receptor ErbB4 on the same neuron as an autocrine signaling. This activation promotes the association of ErbB4 to GluN2B-containing NMDARs, and triggers rapid internalization of surface NMDARs, but not AMPA receptors, in the GABA neurons. Therefore, NMDAR seemed to be both an effector and a target of NRG2/ErbB4 signaling in the cortical interneurons. Consistently, it was previously shown that NRG-induced suppression of NMDAR activation is more pronounced in schizophrenia patients than in controls.131 These results suggest a plausible cellular mechanism by which NMDARs can be selectively internalized in the cortical PV neurons, but not in pyramidal neurons. Together with the GluN2D knockout studies, these findings may offer a novel therapeutic approach for treating schizophrenia by enhancing the NMDAR function selectively in the GABA neurons.

Theoretical findings also offer supportive evidence for a role for NMDAR hypofunction in PV neurons in the development of schizophrenia. A spiking neural network model of spatial working memory, consisting of interconnected excitatory pyramidal cells and inhibitory interneurons in prefrontal cortex, postulated a preferential down-regulation of NMDAR conductance on interneurons, but not simultaneously in both excitatory and inhibitory neurons, in order to increase E/I balance for working memory deficits in schizophrenia.132 The simulation showed that elevated E/I balance state, which seems to occur in schizophrenia, could be increased when the strength of NMDAR conductance on interneurons is robustly reduced while excitatory cells’ NMDAR conductance is maintained. In contrast, when NMDAR conductance on excitatory cells is too low (by reduced E/I balance), the circuit simply could not support persistent activity, so that activity pattern is collapsed during the delay period and the memory was lost. When NMDAR conductance at both pyramidal cells and interneurons is proportionally reduced, E/I balance is unaltered as expected. From this network simulation model, it appears that NMDAR hypofunction selectively on GABA neurons modulates the elevated E/I balance in the prefrontal cortex seen in schizophrenia,
Dual NMDAR hypofunction model for schizophrenia pathobiology. Accumulating evidence from genetic and pharmacological studies lend support for spatially and temporally dissociated NMDAR hypofunction events in schizophrenia pathobiology. The first NMDAR hypofunction occurs in cortical GABA neurons, including PV neurons, during early postnatal development, impairing the cortical circuitry maturation and leading to a variety of fast-spiking neuron-associated abnormalities, including gamma band synchrony deficits, oxidative stress increase, dopamine dysregulation, and disinhibition of pyramidal neurons. These abnormalities could contribute to the emergence of positive, negative and cognitive symptoms. Moreover, the E/I balance increase eventually elicits glutamate spillover during the prodromal period or later, which could produce a second NMDAR hypofunction in pyramidal neurons in response to low level but cumulative excitotoxicity. NMDAR hypofunction in pyramidal neurons may be responsible for spine density alteration of cortical pyramidal cells, which could also contribute to cognitive and negative symptoms as the disease progresses. Therefore, both types of NMDAR hypofunction may contribute to the schizophrenia pathobiology. It is unclear when the first NMDAR hypofunction ends and the second hypofunction starts (shown by dotted lines). The cause of the first NMDAR hypofunction remains to be determined (but see text) and that NMDAR hypofunction at both pyramidal neurons and interneurons is unlikely from the E/I balance perspective.

Fig. 3 Dual NMDAR hypofunction model for schizophrenia pathobiology. Accumulating evidence from genetic and pharmacological studies lend support for spatially and temporally dissociated NMDAR hypofunction events in schizophrenia pathobiology. The first NMDAR hypofunction occurs in cortical GABA neurons, including PV neurons, during early postnatal development, impairing the cortical circuitry maturation and leading to a variety of fast-spiking neuron-associated abnormalities, including gamma band synchrony deficits, oxidative stress increase, dopamine dysregulation, and disinhibition of pyramidal neurons. These abnormalities could contribute to the emergence of positive, negative and cognitive symptoms. Moreover, the E/I balance increase eventually elicits glutamate spillover during the prodromal period or later, which could produce a second NMDAR hypofunction in pyramidal neurons in response to low level but cumulative excitotoxicity. NMDAR hypofunction in pyramidal neurons may be responsible for spine density alteration of cortical pyramidal cells, which could also contribute to cognitive and negative symptoms as the disease progresses. Therefore, both types of NMDAR hypofunction may contribute to the schizophrenia pathobiology. It is unclear when the first NMDAR hypofunction ends and the second hypofunction starts (shown by dotted lines). The cause of the first NMDAR hypofunction remains to be determined (but see text) and that NMDAR hypofunction at both pyramidal neurons and interneurons is unlikely from the E/I balance perspective.

and that NMDAR hypofunction at both pyramidal neurons and interneurons is unlikely from the E/I balance perspective.

UNIFIED HYPOTHESIS OF NMDAR HYPOFUNCTION

NMDARs are expressed in most of cells in the central nervous system from the embryonic stage. Since conventional GluN1 knockout shows perinatal lethality and GluN1 hypomorph mice display more diverse phenotypes than what is observed in schizophrenia, NMDAR hypofunction leading to schizophrenia should have spatial and temporal boundaries. The results of studies utilizing competitive NMDAR antagonists suggest that NMDAR hypofunction at PV-positive GABA neurons causes GABAergic disinhibition and glutamate increase, which in turn elicits dopamine dysregulation. Since synaptic NMDARs in PV neurons are more highly expressed during development than adulthood, NMDA hypofunction on PV neurons during development may contribute to the disease. Consistently, drug manipulation during the postnatal second week by NMDAR antagonists recapitulates several schizophrenia-like phenotypes. Similarly, forebrain GABA neuron GluN1 KO mice confer several behavioral and electrophysiological phenotypes that seem to mimic aspects of schizophrenia. On the other hand, NMDAR hypofunction in cortical pyramidal neurons is also strongly suggested, mainly because the levels of GluN1 mRNA/protein are reduced in prefrontal cortex of patients with schizophrenia in postmortem tissue studies. How do we reconcile these results each other?

Recent clinical studies suggest that elevation in glutamatergic metabolites is present prior to onset of psychosis, which could be originated from disinhibition by GABAergic NMDAR hypofunction. This glutamatergic spillover could explain the subsequent induction of NMDAR hypofunction in cortical pyramidal neurons, because over-activation of NMDARs by glutamate and glycine elicits a homeostatic internalization of NMDARs from neuronal cell surface. Therefore, we speculate that there are two spatially and temporally dissociated NMDAR hypofunction events that are related to schizophrenia pathobiology (Fig. 3). The first NMDAR hypofunction occurs in cortical GABA neurons, including PV neurons, in early postnatal development, which would impair the cortical maturation that causes a reduction of intrinsic excitability and impaired GABA release, thereby leading to disinhibition of pyramidal neurons. Subsequently, the second NMDAR hypofunction is in turn elicited in cortical pyramidal neurons in response to glutamate spillover in the prodromal period. Importantly, neither NMDAR hypofunction alone is fully explanatory. For example, schizophrenia-related GABAergic dysregulation, such as reduced expression of GAD67 and PV, is not observed in excitatory neuron...
GluN1 knockout mice but is consistently reported in the GABAergic GluN1 knockout mice. On the other hand, spine density reduction is induced by GluN1 knockdown in the pyramidal neurons. Spatial reference memory in Morris water maze test is intact in PV-cre/GluN1 KO mice but is severely impaired in aCaMKII promoter-driven GluN1 knockout mice. It is plausible that cognitive decline observed in a subtype of chronic patients may be explained by NMDAR hypofunction in cortical pyramidal neurons. Further studies are warranted to determine the contribution of each NMDAR hypofunction to the disease pathophysiology. It must be noted that NMDAR hypofunction in other cell-types could occur in a temporally-specific manner in addition to these two events, which are not mutually exclusive.

OUTLOOK

The developmental NMDAR hypofunction hypothesis in GABA neurons remains highly speculative, because there is no convincing evidence of reduced NMDAR-mediated glutamatergic neurotransmission onto PV neurons in patients with schizophrenia. One way to address this issue is to identify the regulator molecules that could elicit NMDAR channel down-regulation in cortical GABA neurons. The NMDAR complex comprises hundreds of intracellular proteins, and its function is regulated at many levels, including transcription, translation, post-translation, protein trafficking, channel modulation, and cellular activity, as well as possibly being developmentally regulated. Therefore, any combination of genetic and epigenetic mutations could render NMDAR signaling pathways less active, which may allow schizophrenia to develop. Indeed, many NMDAR-associated genes are listed as a schizophrenia risk gene, such as NR2G2/ErbB4 signaling pathway, which causes NMDAR downregulation selectively in PV neurons. Genome-wide association studies of schizophrenia also uncover genetic polymorphisms in several immune-related genes, which may affect the levels of proinflammatory cytokines, leading to activation of kynurenic pathway. The discovery of abundant expression of KYNA synthesizing enzyme in cortical GABA neurons may allow us to speculate NMDAR hypofunction in GABA neurons induced by the neuroinflammatory stress. The glutathione (GSH) system dysfunction is also seen in schizophrenia. Since NMDAR is required for GSH biosynthesis, MK-801 treatment at PND 7 in rats was shown to reduce GSH levels, which in turn may trigger redox imbalance and further suppression of NMDA currents as a negative spiral. Notably, PV-positive fast-spiking neurons are highly vulnerable to early oxidative stress, perhaps because fast-spiking neurons have an increased demand for GSH. It remains to be tested whether developmental NMDAR hypofunction occurs on PV neurons by elevated oxidative stress.

Alternatively, it will also be beneficial to examine whether animals’ molecular signs following neonatal NMDAR blockade is observed in the postmortem human brain tissues. Neonatal treatment with uncontrollable NMDAR antagonists disrupts the maturation of the fast-spiking property. GluN1-deleted fast-spiking neurons in Ppp1r2-cre/GluN1 KO mutant mice also exhibit the maturation deficits of fast-spiking neurons, such as significantly low instantaneous firing rates and high input resistance in juvenile period (Jeevakumar, unpublished). Therefore, it is tempting to speculate that the signature of NMDAR blockade-mediated maturation deficits in PV neurons could be found in human patient tissues. For example, neonatal repeated exposure to PCP ketamine, or MK-801 consistently disturbs the developmental GluN2B-GluN2A switch that occurs in immature PV neurons during PND 14–21. Consistently, a transcription factor called REST, which facilitates GluN2B-GluN2A switch in neurons, appears to be less functional in schizophrenia. If the increase of GluN2B subunit mRNA was detected in PV neurons of schizophrenia postmortem brains, in particular, at the earlier life stage, it might suggest NMDAR hypofunction in PV neurons in perinatal period.

In conclusion, multiple strands of evidence from the animal studies suggest that there are two spatially and temporally dissociated NMDAR hypofunction events that are related to schizophrenia pathophysiology (Fig. 3). One is the NMDAR hypofunction in early postnatal development on cortical and hippocampal GABAergic interneurons linked to the primary pathophysiology of schizophrenia. The resulting GABAergic deficit-mediated E/I ratio elevation may produce the glutamate spillover, which could result in the homeostatic down-regulation of NMDAR-signaling pathway in cortical pyramidal neurons in prodromal period. Other cell-types, including the reticular and relay nuclei of the thalamus, may also be responsible for some of the symptoms, and these possibilities are not mutually exclusive.

Although technically challenging, it will be important to directly assess the NMDAR hypofunction at the cellular levels in human brains. Recent development of NMDAR-subunit selective allosteric modulators would be promising for potential pharmacological interventions. More coordinated efforts between human and animal studies will be necessary to understand the NMDAR hypofunction leading to schizophrenia and ultimately to reverse the related symptoms.

ACKNOWLEDGEMENTS

We thank Stefan Kolata for his comments on the text. This work was supported by NIH grant K22MH099164 and by R01MH110681.

AUTHOR CONTRIBUTIONS

K.N. was involved in overall concept of paper and figures, literature search, and writing. V.J. was involved in editing text and literature search. K. N. was involved in editing text and design of Figs. 1, 2.

COMPETING INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Howes, O. D. & Kapur, S. The dopamine hypothesis of schizophrenia: version III—the common pathway. Schizophr. Bull. 35, 549–562 (2009).
2. Coyle, J. T. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 38, 920–926 (2012).
3. Lodge, D. & Mercier, M. S. Ketamine and phencyclidine: the good, the bad and the unexpected. Br. J. Pharmacol. 172, 4254–4276 (2015).
4. TCP Phencyclidine: Historical and Current Perspectives, Edward F. Domino, ed. NPP Books, Ann Arbor, USA (1981).
5. Lahti, A. C. et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13, 9–19 (1995).
6. Hunt, M. J. & Kasicki, S. A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo. J. Psychopharmacol. 27, 972–986 (2013).
7. Driesen, N. R. et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol. Psychiatry 18, 1199–1204 (2013).
8. Gonzalez-Burgos, G., Fish, K. N. & Lewis, D. A. GABAA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 2011, 723184 (2011).
9. Stone, J. M. et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 17, 664–665 (2012).
10. Merritt K. et al. Nature of Glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry 73, 665–674 (2016).
11. Jackson, M. E., Homayoun, H. & Moghaddam, B. NMDAR receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 101, 8467–8472 (2004).
12. Homayoun, H. & Moghaddam, B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496–11500 (2007).
13. Gratton, A., Hoffer, B. J. & Freedman, R. Electrophysiological effects of phencyclidine in the medial prefrontal cortex of the rat. Neuropharmacology 26, 1275–1283 (1987).
14. Suzuki, Y. et al. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 114, 769–779 (2002).
15. Jodo, E. et al. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb. Cortex 15, 663–669 (2005).
16. Matta, J. A. The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: a model for schizophrenia. J. Physiol. Paris 107, 434–440 (2013).
17. Monaco, S. A., Gulchina, Y. & Gao, W. J. NMDA subunit composition and plasticity. Neurosci. Biobehav. Rev. 56, 127–138 (2015).
18. Wang, M. et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 77, 736–749 (2013).
19. Nakazawa, K. et al. NMDA receptors, place cells and hippocampal spatial memory. Nat. Rev. Neurosci. 5, 361–372 (2004).
20. Thompson, L. T. & Best, P. J. Place cells and silent cells in the hippocampus of freely-behaving rats. J. Neurosci. 9, 2382–2390 (1989).
21. Le Roux, N. et al. Input-specific learning rules at excitatory synapses onto hippocampal parvalbumin-expressing interneurons. J. Physiol. 591, 1809–1812 (2009).
22. Rujescu, D. et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59, 721–729 (2006).
23. Jentsch, J. D. & Roth, R. H. The neuropsychopharmacology of phencyclidine: a model for schizophrenia. Ann. N.Y. Acad. Sci. 704, 98–116 (1994).
24. Jentsch, J. D. & Roth, R. H. The neuropsychopharmacology of phencyclidine: case series and analysis of the effects of antibodies. Lancet Neurol. 7, 1091–1098 (2008).
25. Moscato, E. H. et al. Acute echinoderms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann. Neurol. 76, 108–119 (2014).
26. Nyiri, G. et al. Large variability in synaptic N-methyl-D-aspartate receptor density on interneurons and a comparison with pyramidal-cell spines in the rat hippocampus. Neuroscience. 119, 347–363 (2003).
27. Masdeu, J. C., Dalmau, J. & Berman, K. F. NMDA receptor internalization by autoantibodies: a reversible mechanism underlying psychosis? Trends Neurosci. 39, 11–16 (2016).
28. Gresa-Arias, N. et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 13, 167–177 (2014).
29. Weinberger, D. R. On the plausibility of “the neurodevelopmental hypothesis” of schizophrenia. Neuropsychopharmacology. 14, 1–11s (1996).
30. Deutsch, S. I., Mastrocolo, J. & Rosse, R. B. Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin. Neuropsychopharmacol. 21, 320–332 (1998).
31. Brown, A. S. & Derkits, E. J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167, 261–280 (2010).
32. Paule, M. G. et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotox. Teratol. 33, 220–230 (2011).
33. du Bois, T. M. & Huang, X. F. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res. Rev. 53, 260–270 (2007).
34. Lim, A. L., Taylor, D. A. & Malone, D. T. Consequences of early life MK-801 administration: long-term behavioural effects and relevance to schizophrenia research. Behav. Brain Res. 227, 276–286 (2012).
35. Jentsch, J. D. & Roth, R. H. The neuropsychopharmacology of phencyclidine: a model for schizophrenia. Ann. N.Y. Acad. Sci. 704, 98–116 (1994).
36. Jentsch, J. D. et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59, 721–729 (2006).
37. Akert, T. et al. Preclinical exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postnatal rats. Psychopharmacology (Berl.) 192, 303–316 (2007).
38. Behrens, M. M. et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318, 1645–1647 (2007).
39. Wang, C. Z. et al. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology 33, 2442–2455 (2008).
40. Coleman, L. G. Jr. et al. Deficits in adult prefrontal cortex neurons and behavior following early post-natal NMDA antagonist treatment. Pharmacol. Biochem. Behav. 93, 322–330 (2009).
41. Kjaerby, C. Impaired GABAergic inhibition in the prefrontal cortex of early postnatal phencyclidine (PCP)-treated rats. Cereb. Cortex 24, 2522–2532 (2014).
42. Jeevakumar, V. et al. Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. Behav. Brain. Res. 282, 165–175 (2015).
43. Jeevakumar, V. & Kroener, S. Ketamine administration during the second postnatal week alters synaptic properties of fast-spiking interneurons in the medial prefrontal cortex of adult mice. Cereb. Cortex 26, 1117–1129 (2016).
44. Contestabile, A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res. Brain Res. Rev. 32, 476–509 (2000).
45. Komuro, H. & Rakic, P. Modulation of neuronal migration by NMDA receptors. Science 260, 95–97 (1993).
46. Desfieux, A. et al. Dual effect of glutamate on GABAergic interneuron survival during cerebral cortical development in mice neocortices. Cereb. Cortex 20, 1092–1108 (2010).
47. Awobulu, M., Lipton, S. A. & Sacher, N. J. Translationally distinct populations of NMDA receptor subunit NR1 mRNA in the developing rat brain. J. Neurochem. 87, 1066–1075 (2003).
48. Hestrin, S. Developmental regulation of NMDA receptor-mediated synaptic transmission at a central synapse. Nature 357, 686–689 (1992).
49. Wang, H. X. & Gao, W. J. Cell-type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology 34, 2028–2040 (2009).
50. Rotaru, D. C. et al. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J. Neurosci. 31, 142–156 (2011).
73. Li, Y.
72. Forrest, D. et al.
75. Woodruff, P. W., McManus, I. C. & David, A. S. Meta-analysis of corpus callosum
74. Elberger, A. J. & Deng, J. Corpus callosum and visual cortex of mice with deletion
et al.
78. Gainetdinov, R. R., Mohn, A. R. & Caron, M. G. Genetic animal models: focus on
et al.
85. Gao, X. M. 
84. Sokolov, B. P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNA is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. 

80. Barkus, C. et al. GluN1 hypomorph mice exhibit wide-ranging behavioral alterations. 
Genes Brain Behav. 11, 342–351 (2012).

81. Bodarky, C. L. et al. Novel environment and GABA agonists alter event-related potentials in N-methyl-D-aspartate NR1 hypomorphic and wild-type mice. 
J. Pharmacol. Exp. Ther. 331, 308–318 (2009).

82. Gandal, M. J. et al. Mice with reduced NMDA receptor expression: more consistent with utism than schizophrenia? Genes. Brain. Behav. 11, 740–750 (2012).

83. Humphries, C. et al. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. 
Neuroreport 20, 2051–2055 (2009).

84. Sokolov, B. P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. 
Neurochemistry 33, 2157–2186 (2008).

85. Weickert, C. S. et al. Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. 
Mol. Psychiatry 18, 1185–1192 (2013).

86. Alkharabs, S. et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. 
J. Neurosci. 16, 19–30 (1996).

87. Dracheva, S. et al. N-methyl-D-aspartic acid receptor expression in the dorso-lateral prefrontal cortex of elderly patients with schizophrenia. 
Am. J. Psychiatry 158, 1400–1410 (2001).

88. Kristiansen, L. V. et al. NMDA receptors and schizophrenia. 
Curr. Opin. Pharmacol. 7, 48–55 (2007).

89. Catts, V. S. et al. A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenics. 
How can we link molecular abnormalities to mismatch negativity deficits? 
Biopol. Biochem. 116, 57–67 (2016).

90. Banerjee, A. et al. Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR dysfunction in schizophrenia. 
Mol. Psychiatry 20, 1091–1100 (2015).

91. Iwasato, T. et al. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. 
Nature 406, 726–731 (2000).
127. Malayev, A., Gibbs, T. T. & Farb, D. H. Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br. J. Pharmacol. 135, 901–909 (2002).

128. Vales, K. et al. 3αSβ-Pregnanolone glutamate, a use-dependent NMDA antagonist, reversed spatial learning deficit in an animal model of schizophrenia. Behav. Brain. Res. 235, 82–88 (2012).

129. Vullhorst, D. et al. A negative feedback loop controls NMDA receptor function in cortical interneurons via neuregulin 2/Erbb4 signalling. Nat Commun. 6, 7222 (2015).

130. Chung, D. W. et al. Dysregulated ErbB4 splicing in schizophrenia: Selective effects on parvalbumin expression. Am. J. Psychiatry 173, 60–68 (2016).

131. Hahn, C. G. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 12, 824–828 (2006).

132. Murray, J. D. et al. Linking microcircuital dysfunction to cognitive impairment: Effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb. Cortex 24, 859–872 (2014).

133. Bygrave, A. M. et al. Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Transl Psychiatry 6, p. e778 (2016).

134. Zweifel, L. S. et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proc. Natl. Acad. Sci. U. S. A. 106, 7281–7288 (2009).

135. Lisman, J. Excitation, inhibition, local oscillations, or large-scale loops: What causes the symptoms of schizophrenia? Curr. Opin. Neurobiol. 22, 537–544 (2012).

136. Pratt, J. A. & Morris, B. J. The thalamic reticular nucleus: a functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery. J. Psychopharmacol. 29, 127–137 (2015).

137. Vukadinovic, Z. NMDA receptor hypofunction and the thalamus in schizophrenia. Physiol. Behav. 131, 156–159 (2014).

138. Nong, Y., Huang, Y.-Q. & Salter, M. W. NMDA receptors are moving in. Curr. Opin. Neurobiol. 14, 353–361 (2004).

139. Pérez-Otaño, I. & Ehlers, M. D. Homeostatic plasticity and NMDA receptor trafficking. Trends. Neurosci. 28, 229–238 (2005).

140. Alvarez, V. A., Ridenour, D. A. & Sabatini, B. L. Distinct structural and ionotropic roles of NMDA receptors in controlling spine and synapse stability. J. Neurosci. 27, 7365–7376 (2007).

141. McKinney, R. A. Excitatory amino acid involvement in dendritic spine formation, maintenance and remodelling. J. Physiol. 588, 107–116 (2010).

142. Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).

143. Watkins, C. C. & Andrews, S. R. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr. Res. 176, 14–22 (2016).

144. Hardingham, G. E. & Do, K. Q. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat. Rev. Neurosci. 17, 125–134 (2016).

145. Steullet, P. et al. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137, 807–19 (2006).

146. Baxter, P. S. et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun. 6, 6761 (2015).

147. Cabungcal, J. H. et al. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol. Psychiatry 73, 574–82 (2013).

148. Tamminga, C. A. & Zukin, R. S. Schizophrenia: evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology. Neuroscience 309, 233–242 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/